Then in 1994, Dupont and Merck entered into a joint venture, and Endo Laboratories re-emerged as their generics division. Over the next two decades, she worked with and promoted the products that had come from Endo.īut in the late 1980s and early 1990s, DuPont started to move into the cardiovascular therapeutic category and the AIDS market. Ammon, with degrees in biology and business, joined DuPont in 1973. DuPont, whose pharma unit was primarily focused on pain management, bought Endo in 1969 and retired the name. The company was founded in 1920 in New York as a family-run business. In fact, most of the compounds prescribed to treat pain have been around for decades, and the competitive edge in this market goes to companies that find novel formulations that are easy for patients to use.Įndo, as a name in pharmaceuticals, has been around a long time, too. Patient convenience and compliance are also driving technology-based pharmas to develop novel delivery mechanisms. According to Visiongain, the global pain-management market is expected to grow at an annual rate of 4.7 percent and will hit $29.7 billion in 2007. This shift in the mentality of treating pain has driven the market into new territory, both in terms of revenue and products. That has to be monitored and logged in their patient forms." Patients are asked how they feel, on a scale of zero to ten. Every patient visit now must be accompanied by an assessment of the patient's pain. Now all the new accreditation standards rate hospitals on how effectively they are assessing and treating pain. And in the past, hospitals were never assessed on how well they were treating pain. Physicians have the opportunity to take their residency in pain management. "There is now a whole specialty in the area of pain management, which was added in the early 1990s. "We are not yet where we need to be, but there is a much better understanding of the need to aggressively treat pain," Ammon says. The patch acts locally on damaged peripheral nerve and soft tissue, but does not cause complete sensory block in the area of application. Topical lidocaineâÂÂs mechanism of action is to stabilize neuronal activity linked with Na+ channel accumulation, which reduces pain signal initiation and transmission. "They were willing to say they were okay when they were not." In the last ten years, there has been a vast change in that attitude, much of it a result of patient education-through the internet, direct-to-consumer advertising, and outreach efforts from patient groups and companies like Endo. "In the old school thinking, patients wanted to please their physicians," Ammon says. Most of those aging consumers will be US baby boomers, who are much less inclined than their Depression-era parents to be stoics about pain. It also has a deep pipeline of patent-protected, in-licensed products and development deals that are setting it up for long-term stability in a global pain-management market that's expected to expand greatly as the population ages.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |